Arch Biopartners Inc.
Arch Biopartners Inc. (ARCH.V) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
arch.v · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Arch Biopartners Inc. (ARCH.V) measures how much investors pay for each dollar of the company's trailing earnings. ARCH.V's current PE ratio of N/A is calculated by dividing its stock price of $0.49 by its TTM earnings per share of -$0.04.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Arch Biopartners Inc.You ARCH.V | $33M | N/A | — | -$0.04 |
 Cannabix Technologies Inc. BLO.CN | $76M | N/A | — | -$0.04 |
 Covalon Technologies Ltd. COV.V | $60M | 27.97x | — | $0.08 |
 C21 Investments Inc. CXXI.CN | $51M | N/A | — | -$0.03 |
 Defence Therapeutics Inc. DTC.CN | $29M | N/A | — | -$0.07 |
 iAnthus Capital Holdings, Inc. IAN.CN | $35M | N/A | — | -$0.01 |
 MedMira Inc. MIR.V | $42M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-0.02 | — | |
2024-09-30 FY2024 | — | $-0.06 | — | |
2023-09-30 FY2023 | — | $-0.05 | — | |
2022-09-30 FY2022 | — | $-0.02 | — | |
2021-09-30 FY2021 | — | $-0.02 | — | |
2020-09-30 FY2020 | — | $-0.08 | — | |
2019-09-30 FY2019 | — | $-0.04 | — | |
2018-09-30 FY2018 | — | $-0.06 | — | |
2017-09-30 FY2017 | — | $-0.03 | — | |
2016-09-30 FY2016 | — | $-0.02 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Arch Biopartners Inc. (ARCH.V) measures how much investors pay for each dollar of the company's trailing earnings. ARCH.V's current PE ratio of N/A is calculated by dividing its stock price of $0.49 by its TTM earnings per share of -$0.04.
Frequently asked questions
ARCH.V pe ratio · 6 questionsARCH.V's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.49 and TTM EPS of -$0.04. Data sourced from Financial Modeling Prep via ARCH.V's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Arch Biopartners Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08